# GEN602 (NCT03775525)

> Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03775525
- Phase: PHASE1
- Status: UNKNOWN
- Sponsor: Genzada Pharmaceuticals USA, Inc.
- Conditions: Advanced Cancer; Gastric Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer Metastatic; Colo-rectal Cancer; Solid Tumor; Solid Carcinoma; Solid Carcinoma of Stomach; Cancer of Stomach; Lymphoma; Sarcoma; Cutaneous T Cell Lymphoma; Head and Neck Squamous Cell Carcinoma; Basal Cell Carcinoma; Cutaneous T-cell Lymphoma; Cutaneous Squamous Cell Carcinoma
- Interventions: GZ17-6.02; Capecitabine
- Enrollment: 127
- Primary outcome: maximum tolerated dose (MTD)
- Primary outcome: Recommended dose of GZ17-6.02 for future phase II clinical studies
- Primary outcome: Dose-limiting toxicity

## Commentary we found

- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gen602-nct03775525